3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Pain
2
Neoplasm Metastasis
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Plasma Cell
1
Myoepithelioma
1
Multiple Myeloma
1
Kidney Neoplasms
1
Humoral Hypercalcemia Of Malignancy
1
Giant Cell Tumors of Bone
1
Desmoplastic Small Round Cell Tumor
1
Chordoma
1
Carcinoma, Renal Cell
1
Ascites
1
Adenocarcinoma
1
Interventions
Gemcitabine
8
pembrolizumab
5
Paclitaxel
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
sargramostim
2
poly ICLC
2
fludarabine
2
Prednisone
2
Oxaliplatin
2
Irinotecan
2
Hydroxychloroquine
2
Erlotinib Hydrochloride
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
temsirolimus
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
rucaparib
1
resiquimod
1
repotrectinib
1
regorafenib
1
pralsetinib
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma
×
Zoledronic Acid
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled